V. Le Morvan

发表

Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.

J. Robert, J. Bonnet, Delphine Meynard, 2007, Oncology reports.

Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.

V. Brouste, S. Mathoulin-Pélissier, I. Soubeyran, 2007, Pharmacogenomics.

Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells

F. Durrieu, A. Savina, V. Le Morvan, 2019, Cancers.

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice

M. Loriot, C. Ged, M. Gaub, 2015, Fundamental & clinical pharmacology.

A functionalized heterobimetallic (99m)Tc/Re complex as a potential dual-modality imaging probe: synthesis, photophysical properties, cytotoxicity and cellular imaging investigations.

N. Leygue, V. Le Morvan, E. Benoist, 2014, Dalton transactions.

Evaluation of antiproliferative and antioxidant activities of the organic extract and its polar fractions from the Mediterranean gorgonian Eunicella singularis.

J. Robert, A. Bouraoui, V. Le Morvan, 2013, Environmental toxicology and pharmacology.

Short curcumin treatment modulates oxidative stress, arginase activity, aberrant crypt foci, and TGF-β1 and HES-1 transcripts in 1,2-dimethylhydrazine-colon carcinogenesis in mice.

J. Robert, A. Laroche-Clary, V. Le Morvan, 2012, Toxicology.

[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].

M. Loriot, C. Ged, M. Gaub, 2014, Bulletin du cancer.

Dynamic assembly of tight junction-associated proteins ZO-1, ZO-2, ZO-3 and occludin during mouse tooth development.

V. Le Morvan, F. Unda, P. Gorry, 2003, Histology and histopathology.

A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival

K. Tarte, I. Mahouche, J. Merlio, 2021, Blood advances.

Selective dysfunction of p53 for mitochondrial biogenesis induces cellular proliferation in bronchial smooth muscle from asthmatic patients.

R. Marthan, P. Berger, H. Bégueret, 2016, The Journal of allergy and clinical immunology.

Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity.

J. Robert, P. Pourquier, A. Laroche-Clary, 2012, Carcinogenesis.

Model‐Based Quantification of Impact of Genetic Polymorphisms and Co‐Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer

J. Robert, N. Dohollou, F. Dalenc, 2020, Clinical pharmacology and therapeutics.

Prognostic Value of PLAGL1-Specific CpG Site Methylation in Soft-Tissue Sarcomas

F. Chibon, P. Lagarde, V. Brouste, 2013, PloS one.

Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients

B. Bui, J. Coindre, C. Bonaïti‐pellié, 2006, International journal of cancer.

Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene

J. Robert, J. Bonnet, U. Zanger, 2008, Cancer Chemotherapy and Pharmacology.

The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models

J. Kanno, J. Toutain, J. Robert, 2009, British Journal of Cancer.

Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.

A. Kauffmann, J. Robert, A. Laroche-Clary, 2012, Pharmacogenomics.

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients

F. Bertucci, S. Salas, A. Italiano, 2015, British Journal of Cancer.

Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model.

F. Pinguet, J. Robert, I. Solassol, 2009, European journal of cancer.

On the use of pharmacogenetics in cancer treatment and clinical trials.

E. Giovannetti, G. Peters, J. Robert, 2014, European journal of cancer.

Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel.

S. Mathoulin-Pélissier, J. Robert, J. Bonnet, 2006, Pharmacogenomics.

Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel.

J. Robert, V. Le Morvan, N. Nief, 2007, European journal of cancer.

FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

S. Mathoulin-Pélissier, Y. Bécouarn, J. Robert, 2014, BMC Research Notes.

FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

S. Mathoulin-Pélissier, Y. Bécouarn, J. Robert, 2014, BMC Research Notes.

Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study

J. Robert, F. Dalenc, W. Jacot, 2019, Clinical pharmacology and therapeutics.

Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines

J. Robert, M. Longy, V. Le Morvan, 2006, British Journal of Cancer.

A functionalized heterobimetallic (99m)Tc/Re complex as a potential dual-modality imaging probe: synthesis, photophysical properties, cytotoxicity and cellular imaging investigations.

N. Leygue, V. Le Morvan, E. Benoist, 2014, Dalton Transactions.

[Normal organoids and their applications in cancer research].

V. Le Morvan, J. Robert, Frédéric Delom, 2021, Bulletin du cancer.

Developmental regulation of a vertebrate homologue of the Drosophila dlg tumor suppressor gene.

J. Daniel, P. Costet, V. Le Morvan, 1996, The International journal of developmental biology.